All lobbying filings

RK Strategies, Inc.

RK Strategies, Inc. filed a Q1 report for Adial Pharmaceuticals, Inc. on April 20, 2026, reporting $10,000 in lobbying income.

Lobbying for Adial Pharmaceuticals, Inc. · Pharmaceutical company

As filed: RK STRATEGIES, INC. for ADIAL PHARMACEUTICALS, INC.

All filings by RK Strategies, Inc. · Everything Adial Pharmaceuticals, Inc. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Income

$10,000

What the client paid this registrant for the period.

Client based in

Virginia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

FDA Issues Related to Addiction H.R. 7091, Expanding Veterans Access to Emerging Treatments Act National Defense Authorization Act, FY27

Defense

FDA Issues Related to Addiction H.R. 7091, Expanding Veterans Access to Emerging Treatments Act National Defense Authorization Act, FY27

Bills named in this filing 1

H.R. 7091
Expanding Veterans’ Access to Emerging Treatments Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.